HuR/ELAV1 Antibody (G-8): sc-365816
- HuR/ELAV1 Antibody (G-8) is a mouse monoclonal IgG1 κ, cited in 9 publications, provided at 200 µg/ml
- raised against amino acids 1-280 of HuR of human origin
- recommended for detection of HuR, HuB, HuC and HuD of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- See HuR/ELAV1 (3A2): sc-5261 for HuR/ELAV1 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for HuR/ELAV1 Antibody (G-8) for WB and IHC(P) applications. These reagents are now offered in bundles with HuR/ELAV1 Antibody (G-8) (see ordering information below).
QUICK LINKS
HuR Antibody (G-8) is a mouse monoclonal IgG1 antibody that detects HuR in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). HuR, also known as HuA, is a member of the Elav-like family of RNA-binding proteins and plays a crucial role in post-transcriptional regulation of gene expression. HuR (G-8) antibody targets a protein predominantly located in the nucleus, where HuR binds to AU-rich elements in the 3′-untranslated regions of target mRNAs, thereby stabilizing these transcripts and preventing their degradation. The ability of HuR to shuttle between the nucleus and cytoplasm is vital, as this movement allows for dynamic regulation of mRNA stability and translation in response to cellular signals. This function is particularly important in cellular stress and tumorigenesis, as HuR is often overexpressed in various cancers, contributing to the dysregulation of genes involved in cell proliferation and survival. Anti-HuR antibody (G-8) enables researchers to gain insights into the regulatory mechanisms of mRNA stability and the role of HuR in both normal physiology and disease states.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HuR/ELAV1 Antibody (G-8) References:
- Clinical significance of HuR expression in human malignancy. | Kotta-Loizou, I., et al. 2014. Med Oncol. 31: 161. PMID: 25112469
- Targeting the multifaceted HuR protein, benefits and caveats. | Zucal, C., et al. 2015. Curr Drug Targets. 16: 499-515. PMID: 25706256
- Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas. | Levidou, G., et al. 2018. Dis Markers. 2018: 4020937. PMID: 29619127
- WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. | Chen, Y., et al. 2019. Mol Cancer. 18: 127. PMID: 31438961
- Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). | Schultz, CW., et al. 2020. Wiley Interdiscip Rev RNA. 11: e1581. PMID: 31970930
- HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes. | Si, R., et al. 2021. JCI Insight. 6: PMID: 34747371
- Role of Human Antigen R (HuR) in the Regulation of Pulmonary ACE2 Expression. | Aloufi, N., et al. 2021. Cells. 11: PMID: 35011584
- HuR affects chemoresistance of small cell lung cancer by regulating FGFRL1 expression. | Duan, XH., et al. 2022. Exp Ther Med. 24: 638. PMID: 36160905
- Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling. | Zhang, Q., et al. 2023. Cell Biosci. 13: 192. PMID: 37848943
- HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1. | You, H., et al. 2024. J Transl Med. 22: 178. PMID: 38369471
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HuR/ELAV1 Antibody (G-8) | sc-365816 | 200 µg/ml | $322.00 | |||
HuR/ELAV1 Antibody (G-8): m-IgG Fc BP-HRP Bundle | sc-540372 | 200 µg Ab; 10 µg BP | $361.00 | |||
HuR/ELAV1 Antibody (G-8): m-IgG1 BP-HRP Bundle | sc-542078 | 200 µg Ab; 20 µg BP | $361.00 |